NGFR and neuroblastoma: Although further research is necessary, the findings provide preclinical evidence for developing a novel immunotherapeutic approach for neuroblastoma based on p75NTR induction in tumor cells and targeting of the upregulated receptor with antibodies conjugated to either toxins or cytotoxic drugs.